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In serum, the major part of vascular endothelial growth factor derives from in vitro degranulation of granulocytes and platelets.
Therefore, plasma may be preferred for vascular endothelial growth factor measurements. However, which specimen is the best
predictor of survival is still debated. The present study analyzed the prognostic value of matched preoperative serum and plasma
vascular endothelial growth factor concentrations in patients with colorectal cancer. To establish the reference range among
healthy people, vascular endothelial growth factor was analyzed in 50 matched EDTA-plasma and serum samples from healthy
blood donors. Preoperatively, in 524 patients with colorectal cancer, matched plasma and serum vascular endothelial growth
factor concentrations were analyzed. In the colorectal cancer patients, the median plasma vascular endothelial growth factor
concentration (44 pg ml
71) was signiﬁcantly (P=0.01) higher than the median plasma vascular endothelial growth factor
concentration (30 pg ml
71) in the healthy blood donors. In serum, no signiﬁcant (P=0.30) difference in the median vascular
endothelial growth factor concentration was found between colorectal cancer patients (268 pg ml
71) and healthy blood
donors (220 pg ml
71). The preoperative vascular endothelial growth factor concentrations were dichotomized by the 95th
percentile of the healthy blood donors (plasma=112 pg ml
71, serum=533 pg ml
71). In univariate survival analyses, both high
plasma vascular endothelial growth factor (4112 pg ml
71) and high serum vascular endothelial growth factor (4533 pg ml
71)
predicted a reduced survival. In multivariate survival analyses, high serum vascular endothelial growth factor (4533 pg ml
71)
independently predicted a reduced survival (HR=1.65, P=0.015), while high plasma vascular endothelial growth factor
(4112 pg ml
71) did not (HR=1.27, P=0.23). This study indicates that preoperative serum vascular endothelial growth factor
apparently is a better predictor of overall survival than the preoperative plasma vascular endothelial growth factor.
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Vascular endothelial growth factor (VEGF) is one of the strongest
promoters of angiogenesis, and it has been indicated, that the pre-
operative serum VEGF concentration is a prognostic marker in a
variety of solid tumours (Salven et al, 1999a; Chin et al, 2000).
In a previous study including 614 patients, it was shown that
pre-operative serum VEGF concentration, independent of Dukes
stage, was a strong predictor of overall survival of patients with
colorectal cancer (CRC) (Werther et al, 2000). However, VEGF is
stored in circulating white blood cells and platelets (Nielsen et al,
1999; Salven et al, 1999b) and several reports have indicated, that
elevated VEGF concentrations in serum may be a reﬂection of
degranulation of platelets and white blood cells during in vitro clot-
ting, rather than a reﬂection of an ongoing angiogenic activity in
the tumour (Webb et al, 1998). In plasma, white cell and platelet
degranulation is minimized by adding anticoagulatives to the blood
samples, and as a consequence, plasma VEGF concentrations are
up to 20 times lower than the matched serum VEGF concentra-
tions (Banks et al, 1998). Therefore, it was suggested that plasma
should be preferred as specimen for VEGF measurements and that
serum was unsuitable (Banks et al, 1998).
The aims of the present study were to compare the prognostic
signiﬁcance of matched preoperative plasma and serum VEGF
concentrations in patients with CRC and to evaluate whether
serum or plasma was the best predictor of overall survival.
MATERIALS AND METHODS
Healthy volunteers
To establish the reference range among healthy people, matched
plasma and serum VEGF concentrations were measured in 50
healthy volunteer blood donors. Their median age was 59 (55–
65) years and there were 30 men and 20 women.
Patients
The study included 524 consecutive patients scheduled to undergo
elective resection of primary CRC. The median age of the patients
at the time of operation was 69 (33–90) years, and 316 men and
208 women were included. All patients had their primary tumours
resected and none were given chemotherapy or radiotherapy before
or after the operation. All patients had histologically veriﬁed carci-
noma localized in the colon or in the rectum and were staged
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identiﬁed patients with solid metastases or disease that had not
been completely resected. The distribution of Dukes’ stages accord-
ing to site of tumour is shown in Table 1. The clinical data
included overall survival for all patients, and because all Danes
are given a computerized central personal registration number,
none of the patients was lost to follow-up. The median follow-
up time was 95 months (range 78–109) and 324 patients (62%)
died during the observation period. The endpoint for survival
analysis was death of all causes.
Sampling of blood
The peripheral blood samples were collected in endotoxin-free sili-
cone coated tubes (Becton-Dickinson, Mountain View, CA, USA)
with EDTA as additive (plasma) or without additive (serum), after
written informed consent in accordance with the Helsinki II
declaration. The plasma samples were centrifuged (3000 r.p.m.,
48C, 10 min) immediately after the aspiration, and the plasma
was removed and stored at 7808C until analyzed. The serum
samples were allowed to clot at room temperature for 30 min
before centrifugation (3000 r.p.m., 48C, 10 min) and the serum
was removed and stored at 7808C until analyzed. Blood samples
were obtained preoperatively from the patients on the day of their
operation, just before skin incision. The blood samples from the
volunteer blood donors were obtained at the time of their routine
donation of blood in the blood bank.
VEGF analysis
Before analysis, the plasma and serum samples were thawed at
room temperature. The VEGF concentration was measured with
a commercially available human VEGF quantitative enzyme linked
immunosorbent assay (ELISA) kit (R&D Systems, Minneapolis,
MN, USA, Cat No: DVE00), according to the instructions given
by the manufacturer. All analyses were made in duplicate and
the mean value was used for statistical calculations.
Statistical analysis
The SAS
1 software package (version 8.1; SAS Institute, Cary, NC,
USA) was used to manage patient data and for statistical analysis.
In the 524 CRC patients, the plasma and serum VEGF concentra-
tions were scored as low if VEGF was less than or equal to the 95th
percentile of the normal controls (112 and 533 pg ml
71 respec-
tively) or otherwise scored as high. In addition, the patients were
grouped into three strata by the 10th and 90th or the 25th and
75th percentiles of their plasma and serum VEGF concentrations.
The end-point for survival analysis was death of any cause. The
Kaplan–Meier method was used to estimate survival probabilities,
and the log rank test was used to test for equality of strata. The
Cox proportional hazard model was used for multivariate analysis.
The assumption of proportional hazards was veriﬁed graphically.
Rank statistics were used to calculate correlation coefﬁcients and
to test hypothesis on location. Tests of independence were done
with the w
2 test. McNemars test was used for paired proportions.
The level of signiﬁcance was set at 5%.
RESULTS
VEGF concentrations in plasma
In the 50 healthy blood donors, the median plasma VEGF concen-
tration was 30 pg ml
71 (range 0–369). There was no signiﬁcant
correlation (rs=0.009, P=0.95) between age and plasma VEGF
among the blood donors and no signiﬁcant difference in plasma
VEGF (P=0.86) between men and women.
In the 524 patients with CRC, the median plasma VEGF concen-
tration was 44 pg ml
71 (range 0–1185). There was no signiﬁcant
correlation (rs=0.05, P=0.21) between age and plasma VEGF among
the CRC patients, and no signiﬁcant difference in plasma VEGF
(P=0.32) between men and women. The percentile plot of the plasma
VEGF measurements in the 524 CRC patients and in the 50 blood
donors is shown in Figure 1A. The median preoperative concentra-
tion of plasma VEGF for patients with CRC was signiﬁcantly
(P=0.01) higher than the medium value for the healthy blood donors.
Stratiﬁed by Dukes stage, the median plasma VEGF concentra-
tion among the CRC patients was as follows: Stage A:
27 pg ml
71 (range 0–440); stage B: 44 pg ml
71 (range 0–1185);
stage C: 44 pg ml
71 (range 0–706), and stage D: 74 pg ml
71
(range 0–543). The median plasma VEGF concentration signiﬁ-
cantly (P=0.001) increased with advanced Dukes stage. Patients
with the primary tumour localized in the colon, had signiﬁcantly
(P=0.01) higher median plasma VEGF concentrations than patients
with the primary tumour localized in the rectum.
VEGF concentrations in serum
In the 50 healthy blood donors, the median serum VEGF concen-
tration was 220 pg ml
71 (range 46–983). There was no signiﬁcant
correlation (rs=0.07, P=0.61) between age and serum VEGF among
the healthy donors, and no signiﬁcant difference in serum VEGF
(P=0.74) between men and women was found.
In the 524 patients with CRC, the median concentration of
serum VEGF was 268 pg ml
71 (range 9–2500). There was no
signiﬁcant correlation (rs=0.05, P=0.21) between age and serum
VEGF among the patients, and no signiﬁcant difference in serum
VEGF (P=0.22) between men and women. The percentile plot of
the serum VEGF measurements in the 524 CRC patients and in
the 50 blood donors is shown in Figure 1B. Thus, the medium
preoperative serum VEGF concentration in the CRC patients
(268 pg ml
71) was higher than the medium serum VEGF concen-
tration in the healthy controls (220 pg ml
71). However, in contrast
to the median plasma VEGF concentration between CRC patients
and healthy blood donors, the difference in the median serum
VEGF concentration was not statistically signiﬁcant (P=0.30).
Stratiﬁed by Dukes stage, the median serum VEGF concentra-
tion among the colorectal cancer patients was as follows: Stage
A: 261 pg ml
71 (range 9–1500); stage B: 266 pg ml
71 (range
15–1975); stage C: 263 pg ml
71 (range 15–2500), and stage D:
304 pg ml
71 (range 19–1475). Patients with Dukes stage D disease
had signiﬁcantly (P=0.001) higher serum VEGF concentrations
compared to patients with Dukes stage A, B and C disease, while
the latter three groups had comparable concentrations. Patients
with the primary tumour localized in the colon, had signiﬁcantly
(P=0.01) higher serum VEGF levels than patients with the primary
tumour localized in the rectum.
Correlation between matched preoperative serum and
plasma VEGF concentrations
The correlation (rs=0.64) between the 524 matched serum and plas-
ma VEGF measurements is shown in Figure 2. Dichotomizing VEGF
in serum and plasma by the 95th percentile in the relevant control
showed that the plasma measurements had signiﬁcantly more posi-
tives than the serum measurements (P=0.01, McNemars test). This
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Table 1 The distribution of Dukes stage stratiﬁed by topographical
tumour localization
Dukes stage Rectum (%) Colon (%) Total (%)
A 42 (18) 19 (6) 61 (12)
B 77 (34) 135 (46) 212 (40)
C 79 (34) 95 (33) 174 (33)
D 32 (14) 45 (15) 77 (15)
Total 230 (44) 294 (56) 524 (100)
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are correlated, grouping by the 95th percentile of normal donors,
signiﬁcantly more positives are identiﬁed by plasma VEGF
Prognostic signiﬁcance of the preoperative VEGF level
In univariate analyses, by classifying the CRC patients in two
groups, based on the upper VEGF limit of the 95th percentile
of healthy controls, it was shown that patients with plasma VEGF
concentrations above 112 pg ml
71 (n=105) had a reduced overall
survival (although not signiﬁcant, P=0.06) compared to the
patients (n=419) with plasma VEGF concentrations equal to or
below this level (Figure 3A). In the group of patients with serum
VEGF concentrations above the 95th percentile of healthy persons
(533 pg ml
71), (n=81), overall survival was signiﬁcantly
(P=0.006) reduced, compared to patients with VEGF concentra-
tions below or equal to this level (n=443) (Figure 3B). In the
subgroup of patients with colon cancer, the patients with plasma
VEGF above 112 pg ml
71 (n=71) had signiﬁcantly (P=0.01)
reduced overall survival, compared to colon cancer patients
(n=223) with lower VEGF concentrations (Figure 4A). This differ-
ence was not shown in patients with rectum cancer (P=0.93),
(Figure 4B). Dichotomizing the serum VEGF, using the cut point
533 pg ml
71, the subgroup of patients with colon cancer and
high VEGF concentration (n=57) had signiﬁcantly (P=0.003)
reduced survival compared to the patients (n=237) with low
VEGF concentration (Figure 5A). This difference was not observed
in the subgroup of patients with rectal cancer (P=0.3) (Figure
5B).
In the above-mentioned calculations, the cut-off point was set
to the upper limit of the 95th percentile of healthy controls.
However, this level may not be the relevant scoring. In order
to study if a trend could be detected, strata were deﬁned by
the 10th and 90th percentiles of the plasma and serum VEGF
concentrations. This division as seen in Figure 6 indicates that
CRC patients with preoperative serum VEGF concentrations
higher than 670 pg ml
71 had a signiﬁcantly (P50.0001)
reduced survival compared to the patients with lower concentra-
tions. Additionally, CRC patients with preoperative serum VEGF
concentrations lower than 76 pg ml
71 had a signiﬁcantly better
prognosis than CRC patients with VEGF concentrations above
this level. Using the 25th and the 75th percentiles for stratiﬁca-
tion shows a less pronounced effect although statistically
signiﬁcant (P=0.02). This effect was not seen with plasma
VEGF.
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Figure 1 (A) Percentile plot of preoperative plasma VEGF levels in the 524 colorectal cancer patients and in the 50 healthy volunteer blood donors. The
upper 95-percentile limit of healthy volunteer blood donors (continuous line) is added to the ﬁgure. (B) Percentile plot of preoperative serum VEGF levels in
the 524 colorectal cancer patients and in the 50 healthy volunteer blood donors. The upper 95-percentile limit of healthy volunteer blood donors (con-
tinuous line) is added to the ﬁgure.
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Figure 2 Scatter plot of the matched preoperative serum and plasma
VEGF measurements in the 524 colorectal cancer patients. The rank corre-
lation is shown (P50.001) and plasma VEGF less than one are set to 1. In
addition, the 95 percentile for plasma and serum VEGF of the healthy blood
donors are shown.
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Figure 3 Survival curves of the 524 colorectal cancer patients dichoto-
mized by the upper limit of the 95th percentile of healthy volunteer blood
donors. The end-point for survival analysis was death of all causes. Differ-
ences between the two survival curves were assessed by the log rank test,
the hazard rate with 95% conﬁdence interval was calculated by the Cox
regression model. The number of events in each group and the number
of patients at risk after each 24-month interval up to 72 months is indicated
below the curve. (A) The two curves represent patients with plasma VEGF
values below or equal to 112 pg ml
71 (n=419, upper curve), and patients
with plasma VEGF above this level (n=105, lower curve). (B) The two
curves represent patients with serum VEGF values below or equal to
533 pg ml
71 (n=443, upper curve), and patients with serum VEGF above
this level (n=81, lower curve).
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Figure 4 Survival curves of 294 colon cancer (A) and the 230 rectal can-
cer (B) patients dichotomized by the upper limit of the 95th percentile of
healthy volunteer blood donors. The end-point for survival analysis was
death of all causes. Differences between the two survival curves were as-
sessed by the log rank test, the hazard rate with 95% conﬁdence interval
was calculated by the Cox regression model. The number of events in each
group and the number of patients at risk after each 24-month interval up to
72 months is indicated below the curve. (A) The two curves represent
colon cancer patients with plasma VEGF values below or equal to
112 pg ml
71 (n=223, upper curve), and colon cancer patients with plasma
VEGF above this level (n=71, lower curve). (B) The two curves represent
rectal cancer patients with plasma VEGF values below or equal to
112 pg ml
71 (n=196, upper curve), and rectal cancer patients with plasma
VEGF above this level (n=34, lower curve).
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Multivariate survival analysis was performed including Dukes stage,
gender, age, topographical tumour localization, and VEGF level
(Table 2). As expected, advanced Dukes stage was an independent
predictor of overall survival. In patients with colon cancer, high
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Figure 5 Survival curves of 294 colon cancer (A) and the 230 rectal can-
cer (B) patients dichotomized by the upper limit of the 95th percentile of
healthy volunteer blood donors. The end-point for survival analysis was
death of all causes. Differences between the two survival curves were as-
sessed by the log rank test, the hazard rate with 95% conﬁdence interval
was calculated by the Cox regression model. The number of events in each
group and the number of patients at risk after each 24-month interval up
to 72 months is indicated below the curve. (A) The two curves represent
colon cancer patients with serum VEGF values below or equal to
533 pg ml
71 (n=237, upper curve), and colon cancer patients with plasma
VEGF above this level (n=57, lower curve). (B) The two curves represent
rectal cancer patients with serum VEGF values below or equal to
533 pg ml
71 (n=206, upper curve), and rectal cancer patients with plasma
VEGF above this level (n=24, lower curve).
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Figure 6 Survival curves of the 524 colorectal cancer patients grouped
into three strata by the 10th and 90th percentiles of the preoperative
serum VEGF concentrations. The end-point for survival analysis was death
of all causes. Differences between the survival curves were assessed by the
log rank test, the hazard rate with 95% conﬁdence interval was calculated
by the Cox regression model. The number of events in each group and the
number of patients at risk after each 24-month interval up to 72 months is
indicated below the curve. The three curves represent colorectal cancer
patients with the following preoperative serum VEGF concentrations: I:
576 pg ml
71; II: 767670 pg ml
71; III: 4670 pg ml
71.
Table 2 Multivariate survival analysis of the 524 colorectal cancer pa-
tients, using the cut-off levels 112 and 533 pg ml
71 for the preoperative
plasma and serum VEGF concentrations respectively. The analysis includes
Dukes stage, gender, age, topographical tumour localization and preopera-
tive serum and plasma VEGF concentrations
HR 95% CI P-value
Dukes stage A 1
Dukes stage B 1.84 1.13–3.00 0.01
Dukes stage C 4.06 2.51–6.56 50.0001
Dukes stage D 29.74 17.6–51.6 50.0001
P-VEGF 4112
Colon 1.27 0.86–1.86 0.23
Rectum 0.81 0.50–1.33 0.41
s-VEGF 4533
Colon 1.65 1.10–2.47 0.015
Rectum 1.44 0.84–2.48 0.19
Rectum vs colon 1.72 1.33–2.23 0.0002
Age (in years) 1.03 1.02–1.04 50.0001
Gender (m/w) 1.35 1.08–1.70 0.009
P-VEGF=plasma VEGF; S-VEGF=serum VEGF; HR=hazard ratio; 95% CI=95% confi-
dence interval.
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71) signiﬁcantly (P=0.015)
predicted a reduced overall survival, while high pre-operative plas-
ma VEGF level (4112 pg ml
71) did not (P=0.23). In patients with
rectal cancer, neither high serum VEGF concentration nor high
plasma VEGF concentration independently predicted a reduced
overall survival (P=0.19 and 0.41 respectively). Additionally,
patients with the tumour located in the rectum had a signiﬁcantly
(P50.0001) worse prognosis than patients with the primary
tumour located in the colon. In Table 3, multivariate survival
analyses using the cut-off points 76 and 670 pg ml
71 are shown.
This survival analysis indicates that the 95th percentile may not
be the relevant clinical cut-off point for serum VEGF. Furthermore,
the analysis showed that the patients with the highest 10% of the
serum VEGF concentrations had a signiﬁcantly (P=0.0005) reduced
survival compared to the CRC patients with lower VEGF concen-
trations, while the patients with the lowest 10% of the serum
VEGF concentrations had a signiﬁcantly (P=0.04) better prognosis
than the patients with higher preoperative serum VEGF concentra-
tions.
DISCUSSION
The present study showed that preoperative concentrations of plas-
ma and serum VEGF in patients with colorectal cancer were higher
than in healthy controls, although the difference in the serum
concentrations between the two groups was not signiﬁcant. Addi-
tionally, the study indicated that high plasma and serum VEGF
levels might be predictors of reduced overall survival in patients
with CRC. In many aspects, the information obtained from the
matched preoperative serum and plasma VEGF measurements were
similar. The preoperative VEGF levels in plasma and serum were
both higher than in healthy controls, and no correlation was found
between gender and age in the two types of specimen. Additionally,
in univariate survival analyses, high VEGF values predicted a
reduced overall survival in both cases, although the preoperative
serum concentration was a better predictor. Moreover, in the
multivariate analyses, a high preoperative serum VEGF concentra-
tion, in the subgroup of patients with colon cancer, independently
predicted a reduced overall survival, while high preoperative plas-
ma VEGF concentration did not.
A signiﬁcant (P50.001, chi-square test) difference in Dukes
stage was found between rectal and colon cancer patients, so that
rectal cancer patients in general had a less advanced disease at
the time of diagnosis. However, in an analysis including plasma
and serum VEGF, topographical tumour localization and Dukes
stage, patients with the tumour localized in the colon, indepen-
dently of Dukes stage, still had signiﬁcantly higher plasma and
serum VEGF levels (P=0.001 and 0.0003 respectively, ANOVA)
than patients with the tumour localized in the rectum. Therefore,
the difference in plasma and serum VEGF levels between rectal
and colon cancer is not simply a reﬂection of the difference in
distribution of Dukes stage, but seems to be a genuine biological
difference between the two tumour types.
Several studies have indicated that serum is unsuitable for VEGF
measurements since the signiﬁcantly higher VEGF concentration in
serum, compared to matched plasma concentrations, may be due
to release of VEGF from platelets during the in vitro coagulation
(Banks et al, 1998; Webb et al, 1998). However, it has recently been
shown that isolated platelets from cancer patients contain more
VEGF than isolated platelets from healthy controls (Salven et al,
1999b) and a very recent study have demonstrated that the serum
VEGF concentrations in cancer patients with normal platelet
counts were higher than in healthy controls with normal platelet
counts (Lee et al, 2000). Platelet aggregation may contribute to
tumour progression by release of a variety of vasoactive and
proangiogenic substances in the tumour (Browder et al, 2000) and
to metastasis by facilitating adherence of disseminated tumour cells
to capillary walls at distant sites (Hejna et al, 1999). Therefore,
although the preoperative serum VEGF concentration is affected
by in vitro degranulation of platelets, the increased platelet-derived
VEGF may inﬂuence the biology of a present tumour in vivo, and
may presumably reﬂect tumour burden at the time of surgery.
Previously, most clinical studies have addressed the prognostic
impact of preoperative serum VEGF concentrations. Recently, it
was demonstrated that plasma VEGF was increased in patients with
colorectal cancer compared with controls (George et al, 2000) and
that high plasma VEGF concentrations tended to occur with more
advanced disease (Nakayama et al, 2000). The present study
supports these observations and indicates furthermore, in a
univariate analysis, that high concentrations may predict a reduced
overall survival. However, in the multivariate analysis, in the
subgroup of patients with colon cancer, high preoperative plasma
VEGF concentration was not an independent predictor of reduced
overall survival while a high preoperative serum VEGF concentra-
tion was. These ﬁndings may indicate that the preoperative serum
VEGF concentration is a better prognostic parameter than the
preoperative plasma VEGF concentration. However, since platelets
and white cells in peripheral blood samples contribute to the
concentration of VEGF in serum, a large prospective clinical study
should investigate the prognostic signiﬁcance of these parameters
and their correlation to the VEGF concentration in serum and
plasma.
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Table 3 Multivariate survival analysis of the 524 colorectal cancer pa-
tients, using the cut-off levels 76 and 760 pg ml
71 for the preoperative
serum VEGF concentrations. The analysis includes Dukes stage, gender,
age, topographical tumour localization, and preoperative serum VEGF
HR 95% CI P-value
Dukes stage A 1
Dukes stage B 1.84 1.13–2.99 0.01
Dukes stage C 4.02 2.49–6.50 50.0001
Dukes stage D 28.16 16.7–47.6 50.0001
S-VEGF=76–670 1
S-VEGF 4670 1.85 1.31–2.61 0.0005
S-VEGF 576 0.62 0.39–0.97 0.04
Rectum vs colon 1.57 1.25–1.97 0.0001
Age (in years) 1.03 1.02–1.04 0.0003
Gender (m/w) 1.38 1.10–1.73 0.04
S-VEGF=serum VEGF; HR=hazard ratio; 95% CI=95% Conﬁdence interval.
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APPENDIX
The following investigators participated in The RANXO5
Colorectal Cancer Study Group
Bispebjerg Hospital: S Schulze, MD, DMSc J Thorup, MD, P Wille-Jørgen-
sen, MD, DMSc; Bornholm Hospital: E Bentzen, MD; Frederiksberg
Hospital: I Christoffersen, MD, P Møller, MD; Frederikssund Hospital: L
Banke, MD, DMSc, D Froberg, MD; Gentofte Hospital: FW Henriksen,
MD, DMSc, P Crone, MD; Glostrup Hospital: P Hesselfeldt, MD, B Hempel
Sparsø, MD, K Lindorff Larsen, MD; Helsingør Hospital: T Asmussen, MD,
J Heiner, MD; Hillerød Hospital: O Hart Hansen, MD, DMSc, H Flyger,
MD, PhD, P Jess, MD, DMSc; Holbæk Hospital: J Iversen, MD, J La
Cour-Andersen, MD, DMSc, B Vennits, MD; Hvidovre Hospital: F Moes-
gaard, MD, DMSc, J Hammer, MD; Hørsholm Hospital: A Fischer, MD,
DMSc, H Galatius, MD; Kalundborg Hospital: L Naver, MD; Køge Hospi-
tal: D Teilum, MD; Nykøbing Falster Hospital: L Holbraad, MD; Næstved
Hospital: O Iversen, MD, DMSc, J Nymark, MD, O Roikjær, MD; Rigshos-
pitalet: LB Svendsen, MD, DMSc, L Vedel, MD; Roskilde Hospital: L Palm,
MD, DMSc, KC Rasmussen, MD; Slagelse Hospital: J Friis, MD, C Lanng,
MD, K Wiboltt, MD; Stege Hospital: NC Jensen, MD, N Hoffman, MD;
Sundby Hospital: T Larsen, MD, J Packler, MD.
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